The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1690
November 27, 2023
View Complete Issue         Table of Contents 2019 
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
November 27, 2023 (Issue: 1690)
The FDA has approved Xacduro (Innoviva), a combination of the beta-lactam antibacterial sulbactam and the beta-lactamase inhibitor durlobactam, for IV treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia caused...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
Article code: 1690c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.